SEC 13F Intelligence

Managers / Q1 2025 · view latest →

Aquilo Capital Management, LLC

CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140

Reported Value
$56M
Q1 2025
Positions
13
Filings on Record
27
2019–present window
Filed
May 15, 2025
original filing

Summary

Aquilo Capital Management, LLC reported $56M in U.S.-listed holdings across 13 positions for Q1 2025.

Its largest position, Blueprint Medicines, represents 13.3% of the portfolio.

Compared with Q4 2024, the fund opened 1 new position and exited 2.

Portfolio Metrics

Turnover
+25.5%
vs prior filed quarter
Top-10 Concentration
+62.4%
share of reported value
Largest Position
+13.3%
Blueprint Medicines
New / Exited
1 / 2
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $226MQ1 ’19Q2 ’19: $288MQ3 ’19: $142MQ4 ’19: $266MQ1 ’20: $257MQ1 ’20Q2 ’20: $496MQ3 ’20: $945MQ4 ’20: $481MQ1 ’21: $553MQ1 ’21Q2 ’21: $385MQ3 ’21: $551MQ4 ’21: $882MQ1 ’22: $680MQ1 ’22Q2 ’22: $293MQ3 ’22: $277MQ4 ’22: $266MQ1 ’23: $241MQ1 ’23Q2 ’23: $180MQ3 ’23: $110MQ4 ’23: $160MQ1 ’24: $133MQ1 ’24Q2 ’24: $104MQ3 ’24: $132MQ4 ’24: $66MQ1 ’25: $56MQ1 ’25Q2 ’25: $0Q3 ’25: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 94.9%ADR: 2.6%Other: 2.5%
  • Common Stock · 94.9% · $53M
  • ADR · 2.6% · $1M
  • Other · 2.5% · $1M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ZYMEZYMEWORKS INCNEW+84.5K84.5K+$1M$1M
AMGNAMGEN INCADDED+35.0K60.0K+$12M$19M
SLNSILENCE THERAPEUTICS PLCSOLD OUT−367.2K0−$3M$0
SUTRO BIOPHARMA INCSOLD OUT−4980−$916$0
DTILPRECISION BIOSCIENCES INCADDED+189.8K726.1K+$1M$3M
BLUEPRINT MEDICINES CORPTRIMMED−45.7K83.9K−$4M$7M
ARWRARROWHEAD PHARMACEUTICALS INTRIMMED−232.5K550.1K−$8M$7M
KYMRKYMERA THERAPEUTICS INCTRIMMED−45.0K138.5K−$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2025

12 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BLUEPRINT MEDICINES CORPCOM13.32%$7M83.9K
2ARWRARROWHEAD PHARMACEUTICALS INhistory →COM12.57%$7M550.1K
3PTGXPROTAGONIST THERAPEUTICS INChistory →COM7.08%$4M81.7K
4KYMRKYMERA THERAPEUTICS INChistory →COM6.80%$4M138.5K
5DTILPRECISION BIOSCIENCES INChistory →COM NEW6.21%$3M726.1K
6ARVNARVINAS INChistory →COM4.54%$3M360.8K
7RGNXREGENXBIO INChistory →COM3.48%$2M271.3K
8ADICET BIO INCCOM3.32%$2M2.46M
9BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS2.61%$1M171.7K
10IMMATICS N.VSHS2.47%$1M304.9K
11RPTXREPARE THERAPEUTICS INChistory →COM2.29%$1M1.29M
12ZYMEZYMEWORKS INChistory →COM1.80%$1M84.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2025$01Nov 12, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 6, 202513F-HRchanges · EDGAR ↗
Q1 2025$56M13May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$66M15Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$132M14Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$104M13Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$133M10May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$160M10Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$110M12Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$180M13Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$241M12May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$266M13Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$277M15Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$293M13Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$680M14May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$882M14Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$551M14Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$385M15Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$553M17May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$481M17Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$945M17Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$496M14Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$257M14May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$266M12Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$142M11Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$288M13Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$226M14May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.